Mabpharm Limited — Capital/Financing Update 2019

Jun 24, 2019

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “ Stock Exchange ”) and Hong Kong Securities Clearing Company Limited (“ HKSCC ”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the “ U.S. Securities Act ”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the prospectus dated May 20, 2019 (the “ Prospectus ”) issued by Mabpharm Limited ( 邁博葯業有限公司 ) (the “ Company ”) for detailed information about the Global Offering described below before deciding whether or not to invest in the Shares thereby being offered. The Company has not been and will not be registered under the U.S. Investment Company Act of 1940, as amended.

Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

— 1 —

==> picture [72 x 86] intentionally omitted <==

Mabpharm Limited 邁博葯業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code : 2181)

STABILIZING ACTIONS, END OF STABILIZATION PERIOD AND LAPSE OF OVER-ALLOTMENT OPTION

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company announces that the stabilization period in connection with the Global Offering ended on June 23, 2019, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

Further information of stabilizing actions undertaken by China International Capital Corporation Hong Kong Securities Limited, the Stabilizing Manager, its affiliates or any person acting for it during the stabilization period is set out in this announcement.

LAPSE OF OVER-ALLOTMENT OPTION

The Stabilizing Manager did not exercise the Over-allotment Option during the stabilization period and the Over-allotment Option lapsed on June 23, 2019.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company announces that the stabilization period in connection with the Global Offering ended on June 23, 2019, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

The stabilizing actions undertaken by China International Capital Corporation Hong Kong Securities Limited, the Stabilizing Manager, its affiliates or any person acting for it during the stabilization period are set out below:

• (i) over-allocation of an aggregate of 117,536,000 Shares in the International Offering, representing approximately 15% of the total number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option;

— 2 —

• (ii) the borrowing of an aggregate of 117,536,000 Shares by the Stabilizing Manager from CDH PE pursuant to the Stock Borrowing Agreement to cover over-allocation of Shares in the International Offering . Such Shares will be returned and redelivered to CDH PE in accordance with the terms of the Stock Borrowing Agreement; and

• (iii) the purchases of an aggregate of 117,536,000 Shares in the price range of HK$1.20 to HK$1.50 per Share (exclusive of brokerage fee of 1%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005%, if any) on the market during the stabilization period, representing approximately 15% of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option.

The last purchase made by the Stabilizing Manager or its agent on the market during the course of the stabilization period was on June 14, 2019 at the price of HK$1.38 per Share (excluding brokerage of 1%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005%).

By order of the Board Mabpharm Limited Jiao Shuge Chairman

Hong Kong, Monday, June 24, 2019

As at the date of this announcement, the executive Directors are Dr. Qian Weizhu, Dr. Wang Hao, Mr. Li Yunfeng and Dr. Li Jing; the non-executive Directors are Mr. Guo Jianjun and Mr. Jiao Shuge; and the independent non-executive Directors are Mr. Guo Liangzhong, Dr. Zhang Yanyun and Dr. Liu Linqing.

— 3 —